All news

Updated warning on kidney impairment for Reclast

Added: Thursday 15 September 2011

The FDA has approved an update to the label for Reclast (zoledronic acid) to reflect the risk of renal failure. Kidney failure is a rare but serious potential outcome associated with the use of Reclast in patients who already have risk factors for renal problems. Zoledronic acid is used to treat bone problems that may occur with cancer. It is also sold under the name Zometa.

+  http://www.oncologystat.com/news/FDA_Drug_Safety_Communication_New_Contraindication_and_Updated_Warning_on_Kidney_Impairment_for_Reclast_Zoledronic_Acid.html


//